Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

View Full Paper
Ask AI
Bookmark
Share

Authors

STSrinivas K. TantravahiCOClaire OligAHAlexander Hinman

Discussion

Loading...

Member takes

Overview

Single arm trial evaluates asciminib combined with TKIs to improve treatment free remission in chronic myeloid leukemia patients.

Key Points

  • Successful treatment free remission was seen in patients after combination therapy with asciminib and TKIs, indicating a feasible approach to manage chronic myeloid leukemia.
  • Patients had previously been treated with tyrosine kinase inhibitors, with a median duration of 5.5 years on treatment before the second discontinuation attempt.
  • This single arm phase II trial enrolled 9 patients to assess the safety and efficacy of asciminib in achieving further treatment free remission.
  • Adverse events occurred in several patients, but therapy was well tolerated overall, suggesting a promising strategy for chronic myeloid leukemia management.

Cite This Study

Tantravahi et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3dchttps://doi.org/10.1182/blood-2025-7293
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  2. 2Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.2025
  3. 3Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results2026
  4. 4A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase2025
  5. 5Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors2025